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Background: The study aimed to assess serum RANKL:OPG ratio, Dkk-1 and deposition of calcium in aortic valve in
relation to the presence of concomitant coronary atherosclerosis in patients with symptomatic calcified aortic
stenosis (CAS).
Methods: OPG, soluble RANKL and Dkk-1 were measured in 218 consecutive patients who were undergoing
cardiac catheterization because of symptomatic CAS. Values of studied compounds were compared between patients
without (Group A) and with (Group B) coronary atherosclerosis. Computed tomography derived Agatston score was
assessed by using 256-slice CT.
Results: Presence of coronary atherosclerosis was related to significantly (p = 0.007) higher OPG and to
significantly (p = 0.004) lower Dkk-1. Coronary atherosclerosis was also associated with a trend towards a decrease of
RANKL. RANKL/OPG Ratios (mean (95% C.I.)) were: 20.04 (16.58; 24.23) in Group A and 12.69 (9.96; 16.17) in Group B,
resp., p = 0.018). After adjustment, the difference in RANKL:OPG ratios was no longer significant. Multivariable regression
underscored the significance of difference in Dkk-1 (pafter adjustement = 0.020). Group A patients had significantly higher
Dkk-1, significantly higher deposition of calcium in aortic valve and were symptomatic in significantly younger age
(p < 0.001) as compared to group B patients: Agatston score (mean (95% C.I.)) 4069.9 (3211.8; 5134.5) and 2413.5
(1821.3; 3198.1), p = 0.007.
Conclusions: Dkk-1 and deposition of calcium in aortic valve differ significantly in relation to the presence/absence of
coronary atherosclerosis in patients with symptomatic CAS. A positive association was found between Dkk-1 and
calcium load in aortic valve in patients with symptomatic CAS and angiographically normal coronary arteries.
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Table 1 Comparison of baseline characteristics of patients
with symptomatic calcified aortic stenosis and without
(Group A) or with (Group B) concomitant coronary
atherosclerosis
Group A Group B P-value
N = 112 N = 106
Age years, mean (SD) 69.7 (11.5) 75.7 (8.7) <0.001
Men N (%) 60 (53.6) 63 (59.4) 0.657
Obesity N (%) 43 (38.7) 34 (32.4) 0.633
Hyperlipidemia N (%) 37 (33.0) 38 (35.9) 0.892
Hypertension N (%) 70 (62.5) 83 (78.3) 0.024
Diabetes mellitus N (%) 33 (29.5) 43 (40.6) 0.172
Smoking (anytime) N (%) 26 (23.4) 41 (39.4) 0.081
IACE therapy N (%) 42 (37.5) 43 (41.0) 0.895
ARB therapy N (%) 12 (10.71) 20 (19.05) 0.170
Statin therapy N (%) 33 (23.7) 51 (48.6) 0.011
Pressure gradient across
the aortic valve (mmHg);
Mean ± SD 44.4 ± 17.9 40.4 ± 15.5 0.128
Median (25th to 75th
percentile)
43 (32 to 57) 41 (28 to 50)
Peak aortic valve velocity (m/s)
Mean ± SD 4.1 ± 0.8 4.0 ± 0.8 0.107
Median (25th to 75th
percentile)
4.2 (3.6 to 4.7) 4.0 (3.4 to 4.4)
Severe aortic stenosis N (%) 100 (89.3) 85 (18.2) 0.088
SD – standard deviation; IACE – inhibitors of ACE; ARB – angiotensin II
receptor blockers.
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Calcified aortic valve disease, a progressive mineralization
of aortic valves, is responsible for the most common valve
malfunction in adult population – aortic stenosis. Every
50th of individuals ≥ 65 years old has calcified aortic
stenosis (CAS), with 80% progressing to symptoms re-
quiring a surgery to prevent death and to improve
quality of life [1,2].
It has been recognized, that the most significant pre-
dictor of clinical progression of calcified aortic valve dis-
ease is the load of calcium in aortic valve [3]. The
process of calcium deposition in aortic valve is a multi-
factorial event where several pathways interact and influ-
ence disease progression [4]. OPG (Osteoprotegerin)/
RANKL (Receptor Activator Of Nuclear Factor Kappa B
Ligand)/RANK cytokine axis and Wingless tail (Wnt)/
Dickkopf-1 (Dkk-1) signaling have been linked to the de-
velopment of atherosclerosis and might be along the
causal pathway in regulation of valvular calcification
in CAS. Published observations suggest that RANKL/
RANK interaction stimulates vascular/valvular calcifi-
cation. Osteoprotegerin acts as a decoy receptor for
the pro-osteoclastic RANKL, and therefore OPG may
inhibit the process of calcification [5]. The OPG:RANKL
ratio determines the net effect on osteoclasts. The effects
of Dkk-1 on bone are mediated by inhibition of Wnt
signaling, which directly impaired new bone formation
and limited OPG expression, thereby shifting the OPG:
RANKL ratio to favor bone resorption [6].
Degenerative aortic valve disease shares many features
with atherosclerosis. The initial plaque of aortic stenosis
is similar to that seen in coronary artery disease [7].
However, a significant proportion of patients with severe
aortic stenosis have no coronary atherosclerosis. There-
fore, the study was designed to asses serum RANKL/
OPG ratio, Dkk-1 signaling and deposition of calcium in
aortic valve in patients with symptomatic CAS in relation
to the presence of concomitant coronary atherosclerosis.
Methods
The research was carried out according to the principles
of the Declaration of Helsinki. Patients gave informed
consent and the Ethics committee of University Hospital
Kralovske Vinohrady in Prague (Czech Rep.) approved
the study.
Study group consisted of 218 consecutive patients who
were undergoing cardiac catheterization being consid-
ered for aortic valve replacement for symptomatic CAS
in a tertiary care institution [8] from 3/2010 – 6/2012.
Patients with bicuspid aortic valve were excluded from
the participation in this study. The history of chronic
kidney disease was an exclusion criterion because caus-
ing disorder of bone and mineral metabolism, and extra-
skeletal calcifications. Furthermore, every patient whounderwent cardiac catheterization was examined on renal
function. Patients with GFR <60 mL/min/1.73 m2 were
excluded. Patients gave informed consent and the local
ethics committee approved the study. Baseline character-
istics of study population are presented in Table 1.
Blood samples were collected during cardiac catheterization.
After standard processing, serum was stored at −70°C
until assayed. Samples were assayed with OPG ELISA kit
(Biovendor, Laboratorni Medicina, Brno, Czech Rep.),
sRANKL ELISA kit (Biovendor, Laboratorni Medicina, Brno,
Czech Rep.) and Dkk-1 ELISA kit (Biovendor, Laboratorni
Medicina, Brno, Czech Rep.), respectively, according to the
manufacturer’s protocol. Limits of detection were: 0.1 pmol/l
of OPG, 0.4 pmol/l of sRANKL, and 0.01 ng/ml of Dkk-1.
Values of circulating OPG, sRANKL, Dkk-1 were com-
pared between patients without (Group A) and with (Group
B) concomitant coronary atherosclerosis (coronary artery
stenosis ≥ 50%). Patients in group A had angiographically
normal coronary arteries and without coronary calcification.
Computed tomography (CT) derived Agatston score
was assessed by using 256-slice Brilliance iCT (Philips
Medical Systems, Best, The Netherlands) (Figure 1).
Scans were performed with prospective ECG gating at
Figure 1 Demonstration of typical noncontrast CT study of a
patient with severe calcified aortic stenosis and extensive
difuse coronary calcifications (picture A) in contrast with
patient without concomitant coronary disease (picture B).
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scoring was used (gantry rotation time 270 ms, 120 kv
tube voltage and 80 mA tube current). For quantifiac-
tion, the data were transferred to commercially available
workstation Brillance Workspace Portal v.2.6.0.27 (Philips
Medical Systems, Best, The Netherlands).Statistical analysis
Continuous data are presented as arithmetic and geo-
metric means for normally and log-normally distributed
variables, respectively, and 95% confidence intervals are
used to describe the amount of uncertainty associated
with estimate of a population mean. For the analysis, the
asymmetrically distributed dependent variables were log-
transformed. The comparison of groups was based on
Student’s t-test and multiple linear regressions, whichTable 2 Comparison of studied compounds between patients
with (Group B) concomitant coronary atherosclerosis
Variable A (N = 112) B (N = 106)
OPG (pmol/l); 6.06 (5.58; 6.58) 7.27 (6.74; 7.84
gmean (95% C.I.)
sRANKL (pmol/l); 121.43 (103.37; 142.64) 92.24 (73.35; 115.99
gmean (95% C.I.)
Dkk-1 (ng/ml); 1.44 (1.25; 1.66) 1.01 (0.87; 1.17)
gmean (95% C.I.)
P-value for comparison A and B.
P1-value for comparison A and B after adjustment for age.
P2-value for comparison A and B after adjustment for age and diabetes mellitus.
P3-value for comparison A and B after adjustment for age, diabetes mellitus, hypert
OPG: P-value for age < 0.001; P-value for diabetes mellitus = 0.007; P-value for hype
for smoking = 0.470.
RANKL: P-value for age < 0.001; P-value for diabetes mellitus = 0.131; P-value for hyp
for smoking = 0.467.
OPG : RANKL Ratio: P-value for age < 0.001; P-value for diabetes mellitus = 0.018; P-v
for smoking = 0.347.
Dkk-1: P-value for age < 0.832; P-value for diabetes mellitus = 0.112; P-value for hyp
for smoking = 0.904.
gmean – geometric mean; C.I. - Confidence Interval.were used to adjust for potential confounders. Categorical
data are presented as absolute frequencies and percent-
ages and were analyzed using Fisher’s exact test and the
proportional odds model. A statistical analysis was per-
formed by statistical software Stata, release 9.2 (Stata Corp
LP, College Station, TX). All statistical tests were evaluated
at a significance level of 0.05.Results
Presence of coronary atherosclerosis was related to sig-
nificantly higher OPG and to significantly lower Dkk-1
in comparison to presence of normal coronary arteries
in patients with CAS (Table 2). Concomitant coronary
atherosclerosis was also associated with a non-significant
trend towards a decrease of sRANKL. RANKL:OPG Ratio
(mean (95% C.I.)) was 20.04 (16.58; 24.23) in Group A and
12.69 (9.96; 16.17) in Group B, respectively, p = 0.018).
After adjustment for variables that significantly influ-
enced levels of OPG (age, diabetes mellitus) and RANKL
(age, hypertension), the difference in RANKL:OPG ratio
between Group A and Group B was no longer significant
(Table 2). Conversely, multivariable regression underscored
the significance of difference in Dkk-1 signaling in relation
to the presence/absence of concomitant coronary athero-
sclerosis in patients with CAS (pafter adjustement = 0.020).
Patients with CAS and without coronary atheroscler-
osis had significantly higher deposition of calcium in
aortic valve and were symptomatic in significantly youn-
ger age as compared to patients with CAS and with con-
comitant coronary atherosclerosis (Table 1, Figure 2):
Agatston score (mean (95% C.I.)) 4069.9 (3211.8; 5134.5)
and 2413.5 (1821.3; 3198.1), p = 0.007.with calcified aortic stenosis and without (Group A) or
P-value P1-value P2-value P3- value
0.007 0.703 0.852 0.933
) 0.238 0.787 0.860 0.977
0.004 0.010 0.016 0.020
ension, hyperlipidemia, and smoking.
rtension = 0.949, P-value for hyperlipidemia = 0.219, P-value
ertension = 0.018, P-value for hyperlipidemia = 0.425, P-value
alue for hypertension = 0.019, P-value for hyperlipidemia = 0.244, P-value
ertension = 0.568, P-value for hyperlipidemia = 0.601, P-value
Figure 2 Calcium deposition in aortic valve in patients with calcified aortic stenosis in relation to the presence of concomitant
coronary atherosclerosis. Group A (N = 112) – patients with CAS and without coronary atherosclerosis, Group B (N = 106) – patients with CAS
and with coronary atherosclerosis.
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Active osteochondrogenic differentiation and signaling
were demonstrated in aortic valves in CAS [9]. Load of
calcium in valve tissue was recognized as the substantial
sign of disease progression. Recent studies have led to
an understanding of the roles of cytokine and cell-
signaling pathways involving OPG/RANKL/RANK and
Wnt in disease pathogenesis. The cross talk between the
two systems seems to be of biological relevance [10,11].
The OPG/RANKL/RANK cytokine axis appears as the
final effectors of most of the osteotropic factors already
identified. The system consists of the transmembrane
protein RANK, its ligand (RANKL), and the soluble re-
ceptor OPG. RANKL, a protein expressed on the osteo-
blast cell membrane, binds to RANK, a receptor locatedon the osteoclast membrane. This cell-to-cell interaction
initiates a cascade of events resulting in activation and
differentiation of osteoclasts. OPG is a soluble decoy re-
ceptor that binds to RANKL, to limit activation of RANK
[12]. Regulation of osteoclastogenesis by osteoblast-
derived OPG and RANKL involves Wnt signaling. Evidence
from animal models and human studies supports an
anabolic role for Wnt signaling in accrual and main-
tenance of bone mass, mediated by enhanced osteo-
blast differentiation/activity with concomitant suppression
of osteoclast differentiation/activity (Figure 3) [6]. The
Wnt pathway is regulated by a large number of antago-
nists, including the Dickkopf family. The Dkk-1, a secreted
protein, is a soluble inhibitor of Wnt, which blocks matur-
ation of osteoblasts [13].
Figure 3 The role of Dickkopf-1 (Dkk-1) in bone development. Adapted from Joseph J. Pinzone et al. [6] (with permission). RANKL, a protein
expressed on the osteoblast cell membrane, binds to RANK, a receptor located on the osteoclast membrane. RANKL – RANK interaction induces
osteoclast differentiation and bone resorption. OPG neutralizes the binding of RANKL to RANK and prevents bone resorption. The Dkk-1 is a
soluble inhibitor blocks maturation of osteoblasts and lowers OPG levels, resulting in reduced bone accretion and increased osteolytic activity.
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to be activated by atherogenic factors [14]. There is a hy-
pothesis according to which calcified aortic valve disease
represents an atherosclerosis-like process involving the
aortic valve [15,16]. Our study, however, which includes
consecutive patients, confirmed previous observations
that about half of patients with severe CAS had angio-
graphically normal coronary arteries. Therefore we de-
signed a study which aimed to asses serum RANKL/
OPG ratio, Dkk-1 signaling and deposition of calcium in
aortic valve in patients with symptomatic CAS in rela-
tion to the presence of concomitant coronary athero-
sclerosis. The study documented significant differences
in serum Dkk-1 signaling and deposition of calcium in
aortic valves in relation to the presence of concomitant
coronary atherosclerosis in patients with symptomatic
CAS. Our understanding of mechanisms controlling ini-
tiation and progression of aortic valve calcification is
limited. Calcification of aortic valve is an actively-
regulated multifactorial process. Study results evoke sug-
gestions that concomitant coronary atherosclerosis influ-
ences progression of calcified aortic valve disease, or
that there are at least two distinct pathogenic entities of
aortic valve calcification.
We suggest that the main finding of this study is that
elevation of serum Dkk-1 was associated with a signifi-
cant increase of load of calcium in aortic valve.
Rosenhek and colleagues [3] demonstrated that the
presence of aortic valve calcium in patients withasymptomatic mild or moderate aortic stenosis was the
single most significant predictor of clinical progression.
The studied population consisted of consecutive patients
who were being considered for aortic valve replacement
because of symptomatic CAS. Patients with CAS and
normal coronary angiography, with significantly higher
Dkk-1 signaling and significantly higher load of calcium
were symptomatic at significantly younger age in compari-
son to patients with CAS and significant coronary
atherosclerosis.
Clinical observational studies showed that aortic valve
calcification is inversely correlated with low bone tissue
mineral density [17,18]. Direct in vivo measurements
confirmed a paradox of simultaneous osteolysis and ec-
topic calcification in the same animal [19]. This evidence
suggests that osteoporosis may contribute to cardiovas-
cular calcification by adding to a pathological micro-
environment that promotes osteogenesis of the aortic
valve. During bone resorption, biochemical factors are
released into the circulation, contributing to vascular
calcification [20]. RANKL – RANK interaction induces
osteoclast differentiation and activation, stimulates bone
resorption, whereas OPG neutralizes the binding of
RANKL to RANK and prevents bone loss. Dkk-1-
mediated inhibition of Wnt blocks maturation of osteo-
blasts. Thereby, Dkk-1 enhances RANKL levels, because
osteoblast precursors produce relatively large amounts of
RANK ligand [21]. It was confirmed by a clinical studies
that serum Dkk-1 expression was highly inversely
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agents that block bone resorption in animal models also
block vascular calcification [23,24]. Dkk-1 antisense oligo-
nucleotide treatment affected bone metabolism by in-
creasing osteoblast numbers and also by reducing RANKL
expression, ultimately decreasing osteoclastogenesis [25].
Monoclonal neutralizing anti-Dkk-1 antibody reduces
osteolytic bone resorption and increases bone formation
in multiple myolema [26]. Our results suggest that it
might be interesting for further research examining the
potential impact of Dkk-1 antagonists on progression of
calcified aortic valve disease.
Conclusion
Circulating Dkk-1 and calcium deposition in aortic valve
differ significantly in relation to the presence of coronary
atherosclerosis in patients with symptomatic CAS. A
positive association was found between serum Dkk-1
signaling and calcium load in aortic valve in patients
with symptomatic CAS and angiographically normal cor-
onary arteries.
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